Status:

COMPLETED

TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients

Lead Sponsor:

Boston Scientific Corporation

Conditions:

Heart Failure, Congestive

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Demonstrate the efficacy of the device-based managed therapy to treat atrial tachycardia and fibrillation (AT/AF) in patients with CHF indication for implant of a CRT defibrillator and to demonstrate ...

Eligibility Criteria

Inclusion

  • chronic symptomatic HF despite stable, optimal drug therapy
  • indication for a cardiac resynchronisation device with defibrillator backup according to current guidelines
  • patients implanted with cardiac resynchronization device with dual (atrial and ventricular) defibrillation capabilities

Exclusion

  • Chronic atrial fibrillation
  • Valvular disease
  • patients who underwent or are planned for ablation of atrial fibrillation
  • cerebral vascular accident/transient ischemic attack within 12 months from implant which lead to relevant impairment
  • preexisting unipolar pacemaker

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2012

Estimated Enrollment :

420 Patients enrolled

Trial Details

Trial ID

NCT00345592

Start Date

October 1 2006

End Date

November 1 2012

Last Update

March 28 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Istituto di Clinica Medica I° e Cardiologia A.O.C.

Careggi, Italy

2

Azienda Ospedale S. Anna

San Fermo Della Battaglia (CO), Italy